Trial Profile
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2024
Price :
$35
*
At a glance
- Drugs Gildeuretinol (Primary)
- Indications Stargardt disease
- Focus Adverse reactions; Registrational
- Acronyms TEASE
- Sponsors Alkeus Pharmaceuticals
- 05 Jun 2023 According to an Alkeus Pharmaceuticals media release, the U.S. FDA has granted Orphan Drug Designation to gildeuretinol (ALK-001). Alkeus plans to submit an NDA for approval of gildeuretinol in 2024.
- 05 Jun 2023 According to an Alkeus Pharmaceuticals media release, the company announced that it has raised a $150 million Series B financing to support the registration and launch of gildeuretinol (ALK-001) for the treatment of Stargardt disease.The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments.Joshua Boger, Ph.D.,the founder of Vertex Pharmaceuticals, has joined Alkeus as Executive chairman.
- 15 Feb 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2025.